DARE-BV1clindamycin phosphate vaginal gel not checked
FollowEvery change as it happens, and a Monday email
Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “One full applicator (5 g) of clindamycin phosphate vaginal gel, 2% (100 mg clindamycin) or placebo gel will be applied intravaginally as a single dose within 1 day of randomization.”In the company’s words, NCT04370548 on ClinicalTrials.gov
- Tested for
- Bacterial Vaginosis
- Main trialPhase 3
- “This is a multicenter, randomized, double-blind, placebo-controlled study of DARE-BV1 (clindamycin phosphate vaginal gel, 2%) (QD x 1 day) compared to placebo vaginal gel (HEC Universal Placebo Gel) (QD × 1 day) for the treatment of bacterial vaginosis. Patients will be evaluated at three time points: a Day 1 Screening/Randomization visit, a Day 7-14 Interim Assessment visit, and a Day 21 - 30 Test of Cure \[TOC\] visit). Patients who discontinue prematurely from the study will receive a safety follow-up phone call between Day 21-30. The total study duration will be approximately one month…”In the company’s words, NCT04370548 on ClinicalTrials.gov
Other drugs for Bacterial Vaginosis
- BPR-101Chengdu Syncor Pharmaceutical Co., Ltd. · Phase 2
- FB-301Freya Biosciences ApS · Phase 2
- WST03 Vaginal MetronidazoleSPH Sine Pharmaceutical Laboratories Co., Ltd. · Phase 2
- GenSci142Changchun GeneScience Pharmaceutical Co., Ltd. · Phase 1
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Completed | 30 Nov 2020 | DARE-BV1 in the Treatment of Bacterial Vaginosis (DARE-BVFREE) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026